Author: Michael Khanoyan, Analyst
AI is reshaping healthcare and biotechnology from both the care-delivery layer and the R&D stack, creating a new class of venture-backed companies targeting large, workflow-intensive markets. In this research, we map emerging AI entrants across healthcare services and biotech R&D, spanning administrative agents, diagnostic tools, patient experience, clinical documentation, drug discovery, autonomous experimentation, molecular design, and biological data platforms.
As a boutique AI-focused investment bank, our goal is to highlight where AI-native business models are gaining traction, how category boundaries are evolving, and where strategic interest may concentrate as these companies scale. Please reach out with any questions or perspectives on the landscape.